{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-23-000033","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.078911+00:00","generated_at":"2026-06-15T12:15:38.309852+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Halozyme stockholders elect three Class I directors and approve 2023 auditor at annual meeting","bullets":["All three Class I director nominees elected: Connaughton, Miyashita, Posard, with majority votes.","Advisory vote on executive compensation approved with 107.6M for vs 4.7M against (95.8% support).","Stockholders chose annual frequency for future advisory votes on executive compensation (110.4M for one year).","Ratification of Ernst & Young as auditor for FY2023 approved with 123.3M votes for (98.8% of votes cast).","Turnout: 124.5M shares represented out of 135.4M outstanding (92% attendance)."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-23-000033","json":"https://secwatch.observer/filing/0001159036-23-000033.json","markdown":"https://secwatch.observer/filing/0001159036-23-000033.md","text":"https://secwatch.observer/filing/0001159036-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/halo-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:15:38.309852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17e8cd4726837ceee787679679b324f41f9d5dbb","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers at the 2023-05-05 meeting.","evidence_excerpt":"Proposal 3 : The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers was as follows: One Year Two Years Three Years Abstain 110,411,006 145,264 1,760,124 83,512","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"2cff2da9b06e37dda51030b9cb70661968e50213","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-05 meeting.","evidence_excerpt":"Proposal 4 : The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: Votes For Votes Against Abstain Broker Non-Votes 123,271,829 1,153,279 103,055 — The foregoing proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"2f52e7805e1023b32abd442933ce160fbc720c63","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the compensation of the Company's named executive officers at the 2023-05-05 meeting.","evidence_excerpt":"Proposal 2 : The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 107,628,112 4,657,698 114,096 12,128,257 The foregoing proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"61699236eb404f7f27c7d3c03a841e1c5d4a3a2c","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Election of three Class I directors to hold office for a three-year term expiring at the 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2023-05-05 meeting.","evidence_excerpt":"On May 5, 2023, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}